Advanced search    

Search: authors:"Raimar Kern"

4 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod

Serono and Novartis. Raimar Kern has received speaker honoraria from Bayer, Biogen Idec, Genzyme, TEVA, Merck Serono and Novartis. Christian Cornelissen is an employee of the Novartis Pharma GmbH

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach

research support from Bayer Healthcare, Biogen Idec, Genzyme, Novartis Pharma AG, Teva, and Sanofi Aventis. Katja Thomas received honorarium from Novartis and Bayer. Raimar Kern received honorarium from

The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

Ziemssen 0 Raimar Kern 0 Christian Cornelissen 0 Zentrum für klinische Neurowissenschaften, Klinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität

Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)

speaker honoraria from Biogen Idec, Genzyme, TEVA and Novartis. Raimar Kern has served on scientific advisory boards, and has received scientific grants speaker honoraria from Bayer, Biogen Idec, Genzyme